FDA Panel Shoots Down Oscient Request

Law360, New York (September 13, 2006, 12:00 AM EDT) -- A panel of the U.S. Food and Drug Administration said Tuesday that Oscient Pharmaceuticals Corp. had not proved its Factive drug is safe and effective enough to use for the treatment of acute bacterial sinusitis.

The leading ingredient in Factive, gemifloxacin, is already approved as a seven-day treatment for community-acquired pneumonia and a five-day treatment for certain cases of chronic bronchitis.

Studies have shown a high risk of skin rashes, though, when the drug is used for sinusitis, an inflammation of the sinuses caused by bacterial,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.